Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma.

Ugurluer G. , Chang K., Gamez M. E. , Arnett A. L. , Jayakrishnan R., Miller R. C. , ...More

Anticancer research, vol.36, no.5, pp.2331-8, 2016 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 36 Issue: 5
  • Publication Date: 2016
  • Title of Journal : Anticancer research
  • Page Numbers: pp.2331-8
  • Keywords: Malignant mesothelioma, next-generation sequencing, molecular targeting therapy, BAP1, CDKNA2A/B, NF2, LUNG-CANCER, GENE, BAP1, STRATEGIES, SURVIVAL, IDENTIFICATION, INACTIVATION, VORINOSTAT, THERAPY, TARGETS


Background/Aim: Malignant mesothelioma is a rare malignancy with limited therapeutic options. Exome-based next-generation sequencing (NGS) techniques may direct the future of molecular targeting and improve systemic therapies for patients with mesothelioma. Materials and Methods: Eleven patients with NGS testing were selected, with a total of 236 somatic cancer-related mutations analyzed. Descriptive and Kaplan-Meier statistics were applied. Results: The median age was 65 years (range=27-73 years); 4 (36%) patients were females. Seven (64%) and four patients (36%) had pleural and peritoneal mesothelioma, respectively. Detectable mutations were found in 86% of the pleural and 50% of the peritoneal mesothelioma patients (overall, 73% of patients). The families of BAP1 (36%), CDKNA2A/B (27%) and NF2 (27%) represented the most frequently mutated genes. The median overall survival for all patients was 20.8 months, with 1- and 2-year survival rates of 91% and 40%, respectively. Conclusion: Genomic alterations as potential therapeutic targets were found by NGS. These findings will help in the development of new screening tools and targeting therapies, and in turn impact the standard-of-care and potentially lengthen disease control and survival periods in the future.